{ }
Warren Coughlin, a Private Wealth Advisor at UBS in Los Angeles, has been recognized in the Forbes Top Next-Gen Best-in-State Wealth Advisor list for 2024, marking his third consecutive inclusion. He leads Presidio Partners, a team specializing in serving tech founders and entrepreneurs, and has advised numerous clients through significant liquidity events. UBS, a global wealth manager, now oversees $5.7 trillion in assets following its acquisition of Credit Suisse.
16:00 15.10.2024
A study led by Dr. Benjamin C. James reveals that cancer patients face significant financial challenges, including a nearly fivefold increase in bankruptcy rates and credit scores averaging 80 points lower than non-cancer patients. The research highlights persistent financial toxicity, particularly among those with bladder, liver, lung, and colorectal cancers, lasting up to 9.5 years post-diagnosis. Factors such as age, race, marital status, and income level contribute to the severity of financial distress, underscoring the need for policy reforms in healthcare and debt collection practices.
UBS projects mid-single digit EPS growth for Disney in FY25, anticipating a 7.2% revenue increase and a rise in EBIT to $3.7B for Q4, driven by improved profitability in direct-to-consumer and box office performance. The firm maintains a Buy rating and a $120 price target, citing potential upside from the deconsolidation of India assets and synergies from Hulu.
15:47 15.10.2024
UBS projects the S&P 500 will reach 6,400 by the end of 2025. This optimistic forecast reflects the firm's confidence in the market's growth potential over the next few years.
15:09 15.10.2024
UBS has raised its S&P 500 price target for year-end 2025 to 6,400, an 8% increase from the previous forecast, while also adjusting the 2024 target to 5,850. The bank anticipates a 9.2% upside driven by earnings growth and improving economic conditions, projecting EPS of $240, $257, and $275 for 2024, 2025, and 2026, respectively. Key factors include stable margins, revenue growth of 4.8% in 2025, and a slight rise in price-to-earnings multiples, although inflation risks could impact the outlook.
15:05 15.10.2024
UBS has raised its year-end target for the S&P 500 to 5,850 points, up from 5,600, citing corporate earnings growth and favorable economic conditions. The index has surged 22.85% in 2024, reaching a record high of 5,859.85 points. UBS also increased its 2025 target to 6,400, driven by anticipated interest rate cuts and strong technology stock performance.
14:21 15.10.2024
UBS Global Research has raised its year-end target for the S&P 500 to 5,850 points, up from 5,600, citing corporate earnings growth and favorable macroeconomic conditions. The index has surged 22.85% in 2024, reaching a record high of 5,859.85 points. Additionally, UBS increased its 2025 target to 6,400, driven by anticipated interest rate cuts and strength in technology stocks.
14:21 15.10.2024
UBS Global Research has raised its year-end target for the S&P 500 to 5,850 points, up from 5,600, citing corporate profit growth and a supportive macroeconomic environment. The index has surged 22.85% in 2024, reaching a record high of 5,859.85 points. UBS also increased its 2025 target to 6,400, anticipating further gains driven by technology stocks and a series of interest rate cuts by the Federal Reserve.
14:21 15.10.2024
Johnson & Johnson reported strong sales growth for its cancer therapy Carvykti and immune disease drug Tremfya in Q3, as new approvals expanded their market reach. This growth comes as the company braces for biosimilar competition to its second-best-selling drug, Stelara, expected in January 2025, which saw a 7% sales decline due to insurer rebates. J&J remains optimistic, raising its operational sales guidance for the year, with plans to expand Tremfya into Crohn’s disease and Carvykti's recent FDA approval for earlier treatment in multiple myeloma.
Frazier Healthcare Partners has acquired DirectMed Imaging, a prominent provider of aftermarket parts and repairs for diagnostic imaging equipment. This partnership aims to enhance DirectMed's growth and market leadership by leveraging Frazier's extensive healthcare expertise and resources. DirectMed, which supports healthcare organizations by extending the life of imaging equipment, plans to expand its capabilities in various imaging modalities.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.